Assetmark, Inc Mirati Therapeutics, Inc. Transaction History

Assetmark, Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 27, 2023	BUY	$27.8 - $45.35 $158,932 - $259,265	5,717 Added 73.1%	13,538 $589,000
Q2 2023 Aug 11, 2023	BUY	$36.13 - $49.49 $57,808 - $79,184	1,600 Added 25.72%	7,821 $282,000
Q1 2023 May 05, 2023	BUY	$36.54 - $54.26 $32,959 - $48,942	902 Added 16.96%	6,221 $231,000
Q4 2022 Feb 10, 2023	BUY	$41.27 - $98.62 $111,635 - $266,767	2,705 Added 103.48%	5,319 $241,000
Q3 2022 Nov 01, 2022	BUY	$59.5 - $86.7 $59,976 - $87,393	1,008 Added 62.76%	2,614 $183,000
Q2 2022 Aug 03, 2022	BUY	$39.16 - $88.71 $55,685 - $126,145	1,422 Added 772.83%	1,606 $108,000
Q1 2022 May 13, 2022	BUY	$75.82 - $150.97 $13,950 - $27,778	184 New	184 $15,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

Stay updated on Assetmark, Inc with notifications on news.